US Pharma MarketingExclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney
Nava Therapeutics discloses it has raised $89M as it targets in vivo CAR-T and kidney delivery with novel lipid nanoparticles. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Nava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney, has raised $89 million, the company told Endpoints News in ...
Source: Endpoints News